Plain-English translation of NCT07306156 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing a new treatment called cells for people with certain blood cancers, particularly those linked to Epstein-Barr virus infection, that have either not responded to standard chemotherapy or have returned after treatment. The medication works by using your own immune cells, which are collected, specially engineered in the laboratory to recognize and attack cancer cells, and then given back to you through an infusion. The goal is to help people whose cancer has proven difficult to treat with conventional approaches.
Many patients with these types of blood cancers don't respond well to standard chemotherapy or experience their cancer returning. This medication offers a different approach—using the body's own immune system to fight the cancer—which may work for people who have exhausted other treatment options.
You likely qualify if…
You likely don't qualify if…
If you qualify, you will first undergo screening tests to confirm your eligibility. Then, your own immune cells will be collected through a process called leukapheresis (similar to donating blood). You'll receive conditioning chemotherapy to prepare your body for the new cells, followed by an infusion of the engineered cells. After treatment, you'll have regular follow-up visits and blood tests to monitor how well the medication is working and watch for any side effects, with longer-term follow-up continuing after your initial treatment period.
AI-generated summary from trial data · Jul 15, 2026 · Not medical advice
China